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Abstract: Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) 
synthesis inhibitor and pro-inflammatory factor. We investigated the role of ADMA in rat 
gastric mucosa compromised through 30 min of gastric ischemia (I) and 3 h of reperfusion (R). 
These I/R animals were pretreated with ADMA with or without the combination of  
L-arginine, calcitonin gene-related peptide (CGRP) or a small dose of capsaicin, all of 
which are known to afford protection against gastric lesions, or with a farnesoid X receptor 
(FXR) agonist, GW 4064, to increase the metabolism of ADMA. In the second series, 
ADMA was administered to capsaicin-denervated rats. The area of gastric damage was 
measured with planimetry, gastric blood flow (GBF) was determined by H2-gas clearance, 
and plasma ADMA and CGRP levels were determined using ELISA and RIA. ADMA 
significantly increased I/R-induced gastric injury while significantly decreasing GBF,  
the luminal NO content, and the plasma level of CGRP. This effect of ADMA was 
significantly attenuated by pretreatment with CGRP, L-arginine, capsaicin, or a PGE2 
analogue. In GW4064 pretreated animals, the I/R injury was significantly reduced and this 
effect was abolished by co-treatment with ADMA. I/R damage potentiated by ADMA  
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was exacerbated in capsaicin-denervated animals with a further reduction of CGRP.  
Plasma levels of IL-10 were significantly decreased while malonylodialdehyde (MDA) and 
plasma TNF-α contents were significantly increased by ADMA. In conclusion, ADMA 
aggravates I/R-induced gastric lesions due to a decrease of GBF, which is mediated by  
a fall in NO and CGRP release, and the enhancement of lipid peroxidation and its  
pro-inflammatory properties.  
Keywords: asymmetric dimethyl arginine; gastric mucosa; ischemia/reperfusion; farnesoid 
X receptor; gastric damage; sensory neurons; calcitonin gene-related peptide; capsaicin 
 
1. Introduction 
Under physiological conditions free L-arginine (L-arg) can be metabolized by arginases to  
L-ornithine and urea, or it can serve as a substrate for nitric oxide synthase (NOS) to synthesize nitric 
oxide (NO) and L-citrulline [1] However, the protein-incorporated L-arg residues are methylated 
through the action of enzymes called protein arginine methyltransferases (PRMTs) known to generate 
NG-monomethyl-L-arginine (L-NMMA), asymmetric dimethyl arginine (ADMA) or symmetric 
dimethyl arginine (SDMA). ADMA and SDMA are present in human plasma at a concentration of  
500 nM–1 µM, while L-NMMA concentration is about 10 times lower [2,3]. Only asymmetrically 
methylated forms of L-NG-monomethyl arginine (L-NMMA) and ADMA, but not SDMA, exert an 
inhibitory effect on NOS [4]. Both L-NMMA and ADMA are nonspecific NO inhibitors and compete 
with L-arg for each of the three isoforms of NOS, endothelial nitric oxide synthase (eNOS), neural 
nitric oxide synthase (nNOS), and inducible nitric oxide synthase (iNOS) [5]. Endogenous 
methylarginine can inhibit 10% of NOS activity. Under a variety of pathological conditions such as 
cardiovascular disorders, plasma ADMA level is highly elevated from three- up to nine-fold, which 
corresponds to 30%–70% inhibition of NO production from eNOS [6,7]. Recently, we reported that the 
concentration of ADMA is increased in animals exposed to stress and ischemia/reperfusion I/R [8] but 
little is known about the factors that can afford gastroprotection against the damage increased by 
ADMA in a stomach compromised by I/R. In particular, whether potent gastroprotectants such as 
capsaicin applied in a small “protective” dose or exogenous calcitonin gene related peptide (CGRP), 
the potent vasodilatatory peptide released from sensory afferent nerves, could affect an increase in 
plasma ADMA levels in rats with acute gastric mucosal I/R injury have not been so far examined. 
Apart from modulation of NO production, ADMA is also involved in organ inflammatory reactions. 
Previous studies revealed that ADMA participates in the process of atherogenesis by enhancing 
production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) [9], monocyte 
adhesion [10], and oxidized low-density lipoprotein accumulation in macrophages [11]. Additionally, 
ADMA was shown to induce cell apoptosis in a dose-dependent manner and contribute to oxidative 
processes [12,13]. Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes ADMA (but not 
SDMA) to dimethylamine and citrulline. In rats, more than 90% of ADMA is eliminated due to the 
activity of DDAH1, which plays an essential role in maintaining NO bioavailability [14].  
Interestingly, activation of the farnesoid X receptor (FXR) through synthetic FXR agonists, such as  
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3-(2,6-dichlorophenyl)-4-(3'-carboxy-2-chlorostilben-4-yl)-oxymethyl-5-isopropylisoxazole (GW4064), 
was shown to increase DDAH1 expression [15]. It was proposed that modulating DDAH1 activity 
through the FXR receptor agonists could be a therapeutic target for treating reduced NO bioavailability 
in congestive heart failure and other cardiovascular diseases [15]. In human hepatocytes, the activation 
of FXR with its agonist, GW4064, increased activity of DDAH-1 and decreased plasma circulating 
levels of ADMA, resulting in significant protection against cisplatin-induced toxicity [16]. Since these 
findings provided an insight into the mechanism by which FXR may affect NO levels through 
modulation of blood ADMA levels via direct regulation of hepatic DDAH1 expression and  
activity [17], we tested the hypothesis that GW4064 could afford protection of I/R-induced gastric 
lesions in the absence and presence of ADMA. Additionally, the determined effect of activation  
and suppression of sensory nerves releasing CGRP [18] in either protection against I/R injury or 
exacerbation of these lesions by ADMA have yet to be explored. 
The excessive generation of reactive oxygen species (ROS), adhesion of neutrophils to endothelial 
cells, the activation of various proinflammatory mediators and the alternation in gastric acid secretion 
have been implicated in the pathogenesis of I/R-induced gastric mucosal injury [19]. Under 
pathological conditions, such as damage by I/R, the superoxide (O2•−) reacts with NO to produce 
peroxynitrite (ONOO−), one of the most powerful and highly damaging oxidants [20].  
Interestingly, more than a 1000-fold production of NO and O2•− increases the formation of ONOO− by 
a 1,000,000-fold [21]. The protective effect of NO synthase inhibitors against I/R injury has been 
described in various tissues [22–24]. It is of interest that donors of NO have also been shown to reduce 
gastric I/R injury [25]. Recent evidence has revealed that ADMA, as a NO inhibitor, may contribute  
to the pathogenesis of acute gastric mucosa injury [26–28] but little is known about whether 
administration of ADMA can influence I/R-induced gastric lesions. In this study, we administered 
ADMA in gradual concentrations to determine the effect of this NO synthase inhibitor on gastric I/R 
lesions, plasma ADMA levels, gastric luminal NO concentration, and changes in the gastric blood flow 
(GBF). We also determined the effects of ADMA in rats with capsaicin-deactivated sensory neurons 
depleted of vasodilatory neuromediator CGRP. Finally, we examined the effect of a synthetic 
prostaglandin (PG) E2 analog, the prototype of gastroprotective substances [29,30], on I/R-induced 
gastric lesions and the accompanying changes in plasma anti-inflammatory (interleukin (IL)-10) and 
proinflammatory cytokine (TNF-α) levels with or without ADMA administration.  
2. Results and Discussion 
Figure 1 shows that ADMA (0.1–40 mg/kg i.g.) pretreatment dose-dependently increased the mean 
area of I/R-induced gastric lesions as compared with the vehicle-control group, which was pretreated 
with vehicle (saline) (p < 0.05). ADMA administered at a dose of 0.1 mg/kg failed to affect the area of 
I/R injury but a significant increase in lesion area was observed starting from a dose of 1 mg/kg of 
ADMA, and this effect was potentiated by ADMA administered in higher doses up to 40 mg/kg. This 
exacerbating effect of ADMA on I/R injury was accompanied by a dose-dependent decrease in GBF  
(p < 0.05). The GBF was significantly decreased by pretreatment with ADMA applied in higher doses 
of 20 and 40 mg/kg (p < 0.05) as compared to that in animals pretreated with ADMA in doses of 1 and 
10 mg/kg. The luminal NO concentration was significantly decreased by ADMA given in a dose of  
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1 or 10 mg/kg (p < 0.05) as compared with the vehicle-control group, and a further significant fall in 
luminal NO concentration was observed when ADMA was applied in higher doses of 20 and 40 mg/kg 
as compared with the respective values of lower doses of ADMA (p < 0.05) (Figure 1). Of note, our 
preliminary studies revealed that ADMA administered alone in a dose of 20 mg/kg (i.g.) did not induce 
gross damage detectable in the gastric mucosa and this effect has been omitted for the sake of clarity.  
Figure 1. Mean lesion area, gastric blood flow (GBF) level, and gastric luminal NO 
concentration after application of vehicle (saline) or ADMA administered in graded doses 
(0.1–40 mg/kg i.g.) followed by exposure to ischemia/reperfusion. Results are mean ± S.E.M. 
of seven rats per group. Significant change (p < 0.05) as compared with the respective 
values in vehicle-control group is indicated by an asterisk. A cross and asterisk indicate 
significant change (p < 0.05) when compared to the values obtained in vehicle-controls and in 
those pretreated with ADMA (1 or 10 mg/kg i.g.).  
 
In intact animals, not exposed to I/R, the plasma ADMA levels were negligible and reached a value 
of 0.22 ± 0.03 μmol/L. As shown in Table 1, ADMA administered i.g. in graded doses ranging from 
0.1 up to 40 mg/kg, produced a dose-dependent increase in the plasma level of ADMA. The increase in 
plasma ADMA levels achieved in rats treated with exogenous ADMA applied in a dose of 20 and  
40 mg/kg reached significantly higher values (p < 0.05) than those recorded when ADMA was 
administered in smaller doses of 1 or 10 mg/kg. 
Data presented in Table 2 indicates that pretreatment with ADMA significantly reduced the luminal 
NO concentration determined after ischemia but before the subsequent reperfusion period (p < 0.05), 
as compared to that measured in vehicle-pretreated controls before reperfusion. Likewise, the luminal 
concentration of NO was significantly inhibited in ADMA-treated animals at the end of 3.5 h of I/R  
(p < 0.05) as compared to vehicle-control animals (Table 2). 
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Table 1. Effect of pretreatment with vehicle (saline) or ADMA administered i.g. in graded 
doses ranging from 0.1 up to 40 mg/kg i.g. on the plasma levels of ADMA in rats exposed 
to 3.5 h of ischemia/reperfusion. Mean ± S.E.M of 6 rats per each group. An asterisk 
indicates a significant (p < 0.05) increase as compared with vehicle-control. An asterisk 
and cross indicate a significant difference (p < 0.05) when compared with the vehicle and 
ADMA applied in doses 1 or 10 mg/kg.  
Experimental group Plasma ADMA concentration (μmol/L) 
Vehicle 1.46 ± 0.22 
ADMA (0.1 mg/kg i.g.) 1.83 ± 0.36 
ADMA (1 mg/kg i.g.) 2.37 ± 0.46 * 
ADMA (10 mg/kg i.g.) 2.65 ± 0.34 * 
ADMA (20 mg/kg i.g.) 3.62 ± 0.43 *+ 
ADMA (40 mg/kg i.g.) 4.95 ± 0.58 *+ 
Table 2. Effect of pretreatment with vehicle (saline) or ADMA (20 mg/kg i.g.) on the 
luminal NO concentration measured in rats after ischemia alone (30 min), and in those with 
ischemia (30 min) followed by reperfusion (3 h). Mean ± S.E.M of 6 rats per each group. 
An asterisk indicates a significant decrease (p < 0.05) as compared to the values obtained 
in vehicle-control rats after ischemia alone, or after ischemia/reperfusion.  
Experimental group Luminal NO (µmol/L) 
After ischemia before reperfusion 
Vehicle 15.2 ± 2.06 
ADMA (20 mg/kg i.g.) 7.6 ± 0.08 * 
After ischemia/reperfusion 
Vehicle 14.6 ± 1.35 
ADMA (20 mg/kg i.g.) 6.3 ± 0.04 * 
Figure 2 shows that the FXR agonist, GW4064, which was reported to increase the DDAH1 
expression and thereby decrease plasma circulating levels of ADMA [17], significantly reduced the 
I/R-induced gastric lesions. This effect was accompanied by a significant increase in the GBF as 
compared to respective values obtained in vehicle-control animals. Concurrent treatment with  
ADMA reversed the GW4064-induced decrease in the area of I/R-induced gastric lesions and the 
accompanying increase in the GBF caused by this FXR agonist. 
The area of I/R-induced gastric lesions was significantly decreased in rats pretreated with low dose 
of capsaicin (0.25 mg/kg i.g.) to stimulate sensory afferent nerves, and in those pretreated with L-arg 
(200 mg/kg i.g.) and CGRP (10 µg/kg s.c.), as compared with the vehicle (saline) pretreated group  
(p < 0.05) (Figure 3). The protective effects of capsaicin, L-arg and CGRP were accompanied by a 
significant increase in GBF (p < 0.05). Co-administration of ADMA (20 mg/kg i.g.) with capsaicin,  
L-arg or CGRP significantly reduced the protective effect of capsaicin, L-arg and CGRP administered 
alone, and these effects were accompanied by a significant decrease in the GBF (Figure 3). 
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Figure 2. Mean lesion area and the changes in gastric blood flow (GBF) in vehicle and 
GW4064 (3 mg/kg i.p.) pretreated rats exposed to 3.5 h of ischemia/reperfusion in the 
absence and the presence of ADMA (20 mg/kg i.g.). Results are mean ± S.E.M of six rats 
per group. Significant change (p < 0.05) as compared with the respective values in  
vehicle-control group is indicated by an asterisk. A cross indicates a significant difference  
(p < 0.05) compared with the vehicle control treated group not treated with ADMA.  
A cross and an asterisk indicate a significant change (p < 0.05) compared to the values 
obtained in rats treated with GW4064 without ADMA. 
 
 
Figure 3. Mean lesion area and the changes in gastric blood flow (GBF) after application of a 
small “protective” dose of capsaicin (CAP, 0.25 mg/kg i.g.), L-arginine (L-Arg, 200 mg/kg i.g.) 
or CGRP (10 µg/kg s.c.). Each was applied alone and in combination with ADMA  
(20 mg/kg i.g.), followed by exposure to ischemia/reperfusion. Results are mean ± S.E.M 
of 6–8 rats per group. Significant change (p < 0.05) as compared with the respective values 
in the vehicle-control group, is indicated by an asterisk. A cross indicates a significant 
change (p < 0.05) compared to the values obtained in the vehicle-control group. An asterisk 
and a cross indicate a significant change (p < 0.05) as compared to the values obtained in 
rats treated with vehicle, capsaicin, L-arg, or CGRP without ADMA.   
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Figure 4 shows that the plasma CGRP level is significantly lower in rats pretreated with ADMA 
compared to the vehicle-control pretreated rats exposed to I/R (p < 0.05). Capsaicin-induced ablation 
of sensory nerves further reduced the plasma CGRP levels in the presence of ADMA. Moreover, 
ADMA administered to rats with capsaicin denervation markedly increased the mean lesion area and 
significantly decreased GBF compared to the ADMA-treated control group without this denervation 
(Figure 4). Concurrent treatment with CGRP reversed the increase in the mean lesion area, the fall in 
plasma CGRP level, and GBF induced by ADMA in capsaicin-denervated animals (p < 0.05) (Figure 4). 
Figure 4. Mean lesion area of ischemia/reperfusion-induced damage, the alterations in the 
gastric blood flow (GBF), and the plasma CGRP levels in rats pretreated with ADMA 
alone or ADMA given in combination with CGRP in rats with or without capsaicin-induced 
denervation. Results are mean ± S.E.M of six to eight rats per group. Significant change  
(p < 0.05) as compared with the respective values in vehicle (saline)-control group is 
indicated by asterisk. A cross and asterisk indicate significant change (p < 0.05) as 
compared with vehicle-control group and with rats treated with vehicle or ADMA alone 
(left panel). Significant difference (p < 0.05) between the respective values in the vehicle 
(saline)-control group and the vehicle-control with capsaicin denervation, is indicated by  
a cross. A double asterisk denotes the significant change (p < 0.05) as compared with the 
respective values in vehicle-controls treated with ADMA without capsaicin denervation.  
A cross and a hash indicate significant change (p < 0.05) compared to the values obtained 
in capsaicin-denervated rats treated with ADMA without concurrent treatment with CGRP. 
 
Results presented in Figure 5 confirm our previous observation [8] that plasma ADMA levels and 
malondialdehyde (MDA) concentration in gastric mucosa are significantly increased in rats exposed to 
I/R (p < 0.05) as compared with intact rats that did not undergo any procedures. The increase of 
plasma level of ADMA following the gastric I/R injury demonstrated in our previous work [8] was 
used in this present study as reference value to compare values of plasma ADMA levels in rats 
pretreated with a small “protective” dose of capsaicin [18] and CGRP, both affording significant 
gastric protection against I/R injury. As shown in Figure 5, the plasma ADMA levels and MDA 
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content were significantly elevated in rats exposed to I/R. Pretreatment with L-arg, CGRP, capsaicin or 
superoxide dismutase (SOD), a potent antioxidant, significantly decreased plasma ADMA levels and 
MDA concentration in gastric mucosa (p < 0.05). 
Figure 5. Plasma ADMA levels and MDA concentration in the gastric mucosa of intact 
rats, and those pretreated with vehicle (saline), L-arginine (200 mg/kg i.g.), CGRP  
(10 µg/kg s.c.), capsaicin (CAP) (applied in small protective dose (0.25 mg/kg i.g.)) or 
superoxide dismutase (SOD, 5000 U/rat i.p.) and exposed to 3.5 h of ischemia/reperfusion. 
Results are mean ± S.E.M of 7 rats per group. Significant change (p < 0.05) as compared 
with the intact group, is indicated by an asterisk. A cross indicates significant change  
(p < 0.05) as compared with vehicle-pretreated rats exposed to 3.5 h of I/R. 
 
 
Pretreatment with ADMA significantly increased the plasma level of pro-inflammatory cytokine 
TNF-α and produced a significant decrease in the plasma level of anti-inflammatory cytokine IL-10 as 
compared to the vehicle-control group (Figure 6). In rats pretreated with 16,16 dimethyl (dm) PGE2, a 
synthetic prototype of a cytoprotective agent [29], a significant decrease in plasma TNF-α level was 
observed, and the area of I/R-induced gastric lesions was significantly attenuated by pretreatment with 
this arachidonate metabolite analog. The pretreatment with dmPGE2 also reversed the decrease in 
plasma IL-10 levels and the fall in the GBF observed in rats exposed to I/R with or without the 
concurrent treatment with ADMA (Figure 6). 
According to the data presented, ADMA could be a noxious factor, which enhances the acute 
mucosal damage within the gastrointestinal (GI) tract. First, we confirmed that plasma ADMA 
concentration was enhanced in rats with I/R injury [8] along with a profound rise in the gastric MDA 
content in these animals. Second, the evidence presented herein indicates that pretreatment with ADMA 
markedly decreased GBF and the luminal NO concentration, which resulted in an enhancement of the  
I/R-induced lesions. In another study, Li et al. [27] demonstrated that treatment with exogenous ADMA 
aggravated the ethanol-induced gastric lesions because ADMA inhibited NO release. In addition, 
Wang et al. [26] observed that ADMA content in gastric juice was markedly elevated in rats with 
ethanol-, indomethacin-, and cold stress-induced gastric lesions. Our results are in keeping with these 
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observations and demonstrate that this asymmetric arginine derivative inhibits NO synthase activity 
and NO content while exacerbating I/R-induced gastric damage, as it was originally observed in the 
animal model of myocardial reperfusion injury [31]. 
Figure 6. Mean lesion area, the alterations in GBF, and the plasma concentrations of 
proinflammatory cytokine TNF-α and anti-inflammatory cytokine IL-10 in rats pretreated 
with ADMA alone or ADMA applied in combination with synthetic prostaglandin  
E2 derivative, 16,16 dmPGE2, and exposed 30 min later to gastric ischemia/reperfusion. 
Results are mean ± S.E.M of 8 rats per group. Significant change (p < 0.05) as compared 
with the respective values in the vehicle (saline)-control group, is indicated by an asterisk. 
A cross indicates the significant difference (p < 0.05) between the values obtained in 
vehicle-controls with and without ADMA administration. An asterisk and a cross indicate 
significant change (p < 0.05) as compared with the vehicle group in the presence of ADMA. 
 
In previous studies [32,33], the inhibition of NO synthesis by N(G)-nitro-L-arginine methyl ester  
(L-NAME) prior to ischemia aggravated I/R-induced gastric damage, but administration of this 
inhibitor prior to reperfusion reduced the I/R damage. We demonstrated in this study that ADMA 
aggravated I/R-induced gastric damage and L-arg, the substrate for NO synthesis, partially attenuated 
the aggravation of I/R injury induced by ADMA which is consistent with the two original observations 
by Kim et al. [32] and Kobata et al. [33] concerning similar aggravation effects of synthetic NO 
synthase inhibitor, L-NAME on I/R-induced gastric mucosal damage. Indeed, ADMA is considered a 
novel cardiovascular risk factor and its deleterious effect on endothelial NO-synthase activity in the 
cardiovascular system may be antagonized by concomitant supplementation with L-arg [34]. Our 
results are corroborative with this notion and demonstrate that pretreatment with exogenous L-arg, 
which afforded gastroprotection and hyperemia in the stomach, also decreased elevated plasma levels 
of ADMA and decreased MDA concentrations in the gastric mucosa in rats exposed to I/R. Taken 
together, these results confirm the important action of ADMA and L-arg in the severity of mucosal and 
cardiac damage and protection of the GI-tract and cardiovascular systems. 
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Our present study revealed that pretreatment with ADMA, which dose-dependently raised plasma 
ADMA increments, and also dose-dependently reduced the gastric luminal NO content. Of note, the 
inhibitory effect of ADMA on luminal NO release was documented both after completion of ischemia 
just before reperfusion, and was also observed at the end of I/R. Previous studies documented that NO 
could be essential for the mechanism of gastroprotection, in part, by NO-inhibition of gastric acid 
secretion [35]. NO inhibits gastric mucosal acid secretory activity via suppression of gastrin-induced 
histamine release through a pathway in which NO activates guanylate cyclase [36]. This action has 
been documented by a NO-induced increase in cGMP levels and a reduction of gastrin-induced 
calcium influx [36]. Furthermore, NO, as a new type of gastric acid inhibitor is expected to decrease 
histamine levels in the stomach [37]. Since hyperacidity is considered to be one of the risk factors 
responsible for impairment of the gastric mucosal barrier that may contribute to peptic ulcer disease, 
the ADMA-induced inhibition of NO release in our study can explain the enhanced susceptibility of 
gastric mucosa to lesions induced by I/R where gastric acid plays a role [38]. The gastric mucosal and 
luminal environment act as a significant source of nitrating and nitrosating agents, because at acidic 
pH levels in the stomach, the nitrite generates different nitrogen oxides depending on the local 
microenvironment (redox status, gastric content, pH, inflammatory conditions), including NO, nitrogen 
dioxide (NO2), dinitrogen trioxide (N2O3), and peroxynitrite [39]. Thus, both the gastric lumen and 
mucosa contain putative targets for nitration in the form of endogenous and exogenous proteins 
exerting an impact on local processes including ulcerogenesis. 
Our data indicates that ADMA may attenuate the protective activity of a potent vasodilator, CGRP, 
which is released from afferent sensory nerve endings in the rat stomach. This suggests that ADMA 
can interact with the activity of sensory afferent nerves. We demonstrated previously that the 
activation of sensory afferent nerves helps to maintain a physiological gastric mucosal barrier against 
the damaging activity of various factors [40,41]. In our present study, pretreatment with both CGRP or 
capsaicin applied at the small dose that was shown to afford gastroprotection against acute gastric 
injury [18], decreased plasma concentration of ADMA and the lipid peroxidation product MDA. 
Moreover, pretreatment with ADMA further exacerbated the damage in rats with functional ablation of 
sensory nerves caused by capsaicin in gastric mucosa exposed to I/R. This exacerbating effect of 
ADMA in capsaicin-denervated rats was accompanied by a marked fall in GBF and a further decrease 
in plasma CGRP concentration compared to those observed in rats with capsaicin denervation alone. 
These effects were reversed by the supplementation of CGRP co-administered with ADMA in rats 
with capsaicin denervation. This reveals a new mechanism of ADMA-induced exacerbation of I/R 
injury by an impairment of vasodilatory neuropeptides such as CGRP, released from these nerves. 
Taken together, CGRP released from afferent sensory nerve endings is influenced by ADMA because 
its release is decreased by treatment with this NO synthesis inhibitor along with the aggravation of 
gastric mucosal I/R injury. 
Herein, we have demonstrated an increased plasma level of proinflammatory cytokine TNF-α and 
decreased anti-inflammatory IL-10 plasma level associated with ADMA administration in animals 
exposed to I/R. This is corroborative with previously observed elevations of TNF-α and IL-1β plasma 
levels in animals subjected to gastric erosions induced by water immersion and restraint stress [13]. 
This increase in proinflammatory cytokines in damaged gastric mucosa could be due to inflammasomes, 
which are the multi-protein complexes that are activated by pathogen and danger associated molecular 
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pattern molecules (PAMP and DAMPs, respectively), leading to the processing of IL-1β and IL-18 by 
caspase-1 [42]. Involvement of the nucleotide-binding oligomerisation domain receptors protein 
(NLRP) inflammasomes have recently been reported in gastrointestinal immune responses [43], 
myocardial I/R injury [44], and acute stroke [45]. Thus, the importance of IL-1β which functions as a 
prominent and early mediator for inflammation in the I/R injury cannot be excluded as a primary 
mediator of ADMA-induced exacerbation of gastric I/R lesions. But this hypothesis requires further 
study. Among the factors capable of exerting an inhibitory effect on ADMA-induced exaggeration of 
I/R lesions were PGs, which are considered to be prototypes of gastric cytoprotection in vivo [46] and 
in vitro [47]. We have previously demonstrated that pretreatment with exogenous 16,16 dmPGE2 
exerts gastroprotection against I/R-induced gastric damage [40], and PG were also reported to act as 
primary mediators of gastric ischemic preconditioning known to exhibit a potent protective activity 
against I/R-induced gastric lesions [48]. Indeed, as shown in this study, pretreatment with the PGE2 
analogue attenuated gastric I/R injury in the presence of ADMA, abrogated the increase in plasma 
level of TNF-α, and counteracted the apparent fall in anti-inflammatory cytokine IL-10 observed in I/R 
animals treated with this NO synthase inhibitor. This indicates that exogenous PG could be considered 
effective agents in the protection against ADMA perpetuation of the lesions induced by I/R. 
Moreover, we demonstrated that the application of antioxidative SOD decreased plasma levels of 
ADMA and gastric tissue concentrations of MDA, which were both increased after exposure to I/R. 
This corresponds to our previous observation that treatment with ADMA resulted in decreased mRNA 
expression for SOD [13]. Taken together, ADMA seems to enhance the lipid peroxidation product 
MDA by inhibition of SOD, and this may contribute to exacerbation of gastric damage caused by I/R. 
Our results are in agreement with the observation by Wu et al. [49] that the increased lung damage 
induced by cerebral I/R injury in rats is correlated with elevated plasma ADMA levels. Moreover, we 
also observed elevated plasma ADMA concentrations of rats exposed to stress [8]. Liu et al. [50] 
demonstrated that stimulation of sensory nerves resulting in CGRP release caused a decrease in 
ADMA concentration and ameliorated the damaging effect of ethanol on gastric mucosa. Our data 
refers to Chen et al. [51] who observed that cultured dorsal root ganglia neural cells co-incubated with 
ADMA decreased CGRP mRNA expression and inhibited the release of CGRP in the culture medium. 
However, Lu et al. [52] observed that the ADMA level in serum is increased more in aged (24 months) 
rats than in young animals (six months), but in their study no difference in mRNA expression for CGRP  
in ADMA-treated rats was noted. In contrast, CGRP production was decreased in spontaneously 
hypertensive (SHR) rats and this effect was accompanied by elevated plasma levels of ADMA [53].  
In our present study, the supplementation of ADMA-treated rats with exogenous CGRP attenuated  
I/R-induced gastric lesions potentiated by ADMA and reversed in part, the accompanying decrease in 
GBF and plasma CGRP levels in rats with or without capsaicin denervation in the presence of ADMA. 
3. Experimental Section  
3.1. Animals, Ischemia/Reperfusion Injury, Afferent Sensory Nerves Ablation 
Male Wistar rats with average weight of about 250 g were fasted for 24 h before the exposure to I/R 
with free access to drinking water. The study was approved by the Institutional Animal Care and Use 
Int. J. Mol. Sci. 2014, 15 4957 
 
 
Committee of Jagiellonian University Medical College in Cracow, Poland and run in accordance with 
the statements of the Helsinki Declaration regarding handling of experimental animals. 
Acute I/R gastric lesions were induced in 120 rats as described previously [38,54,55]. Briefly, under 
pentobarbital anesthesia (60 mg/kg i.p.), the abdomen was opened, and the celiac artery was identified 
and clamped for 30 min followed by removal of the clamp to obtain reperfusion. After 3 h of I/R the 
gastric lesions were scored and the functional parameters described below were determined. 
Rats with intact sensory nerves (series A) were randomized to the groups (6–8 rats each) and were 
administered 30 min before I/R with: (1) ADMA (0.1–40 mg/kg i.g.); (2) L-arg (200 mg/kg i.g.);  
(3) capsaicin (0.25 mg/kg i.g.); and (4) CGRP (10 µg/kg s.c.) alone or applied in combination with 
ADMA administered in the dose of 20 mg/kg i.g., which was selected based on the dose-dependent 
enhancement of the area of I/R injury in rats treated with this NO synthase inhibitor. In addition, the 
effect of the FXR agonist, GW4064 (3 mg/kg i.p.), which has been shown to increase the expression of 
DDAH-1 and to decrease the circulating levels of ADMA [15–17], was measured in rats of series A 
with and without ADMA administration, and exposed to 3.5 h of I/R.  
A separate group of rats (series B) was administered capsaicin for three days at a dose of 25, 50 and 
50 mg/kg (total dose: 125 mg/kg s.c.) to induce functional ablation of afferent sensory nerves as 
described previously [54]. After two weeks, rats of series B were pretreated with ADMA (20 mg/kg i.g.) 
alone or in combination with CGRP (10 µg/kg s.c.) and exposed to standard 3.5 h of I/R. In all series 
of rats, vehicle-(saline) control groups, exposed to I/R were used as a comparison for particular 
compounds tested in this experimental model of gastric lesions. 
Rats of series C were pretreated with L-arg (200 mg/kg i.g.), CGRP (10 µg/kg i.g.), capsaicin  
(0.25 mg/kg i.g.) and SOD (5000 U/rat i.p.), 30 min before the exposure to standard I/R. Rats of series 
D received the pretreatment with vehicle (saline) or 16, 16 dm PGE2 (5 µg/kg i.g.) with or without the 
combination of ADMA (20 mg/kg i.g.) applied 30 min before the I/R.  
In series E, rats were administered saline and exposed to 30 min of ischemia alone, and blood 
samples were collected for NO luminal content and ADMA plasma level determination. 
All tested compounds were of analytical grade and were purchased from Sigma-Aldrich 
(Schelldorf, Germany).  
3.2. Determination of Gastric Blood Flow and the Area of Gastric Lesions 
After the end of 3 h of I/R, the animals of series A–D were anesthetized with pentobarbital  
(60 mg/kg i.p.), the abdomen was opened, and the stomach was exposed to measure GBF by means of 
the H2-gas clearance technique as described previously [54,56]. The GBF was measured in the fundic 
part of the gastric mucosa not involving mucosal lesions. Average values of three measurements were 
determined and expressed as a percentage of the change of the value determined in intact rat stomachs. 
The area of gastric lesions was determined with computer planimetry (Morphomat, Carl Zeiss,  
Berlin, Germany) by a person who did not know which experimental group the animals belonged to. 
3.3. Determination of Luminal NO Release and the Gastric Mucosal MDA Content 
The lumen concentration of NO was quantified indirectly as nitrate (NO3−) and nitrite (NO2−) levels 
in the gastric contents, using the nitrate/nitrite kit purchased from Cayman Lab, Ann Arbor, MI, USA 
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as described previously [57]. This method is based on the Griess reaction and generation of 
chromophore absorbing at 595 nm, according to the original procedure [58]. Since NO released  
by epithelial cells into the gastric lumen is quickly transformed into NO3− and NO2− [59], we 
photometrically measured the sum of both of these products of NO-synthase as an index of NO 
production by the enzyme in the gastric mucosa. For this purpose, the gastric contents were aspirated 
at the end of 3.5 h of I/R just before removal of the stomach following the i.g. injection of 1 mL of 
saline to wash out the lumen contents. In some experiments, the gastric luminal content was collected 
immediately after the end of 30 min of ischemia in order to check whether treatment with ADMA 
results in early inhibition of NO before the subsequent period of reperfusion.  
After centrifugation for 10 min at 3000 rpm, the samples were mixed with Griess reagent  
(Cayman Lab, Ann Arbor, MI, USA).  
To determine MDA tissue concentration the colorimetric assay for lipid peroxidation (Bioxytech  
LPO-586, Oxis, Portland, OR, USA) was used as described previously [13]. In brief, about 600 mg of 
gastric mucosa was excised, quickly washed in a test tube and 20 μL 0.5 M butylated hydroxytoluene 
was added in order to prevent sample oxidation. This sample was subsequently homogenized in 20 mM 
Tris for 15 s. in pH 7.4. Then homogenate was centrifuged (3000× g at 4 °C for 10 min) and the clear 
supernatant obtained was immediately stored at −80 °C prior to testing. The colorimetric assay used to 
determine MDA concentration in gastric mucosa is based on the reaction of a chromogenic reagent  
N-methyl-2-phenylindole with MDA and 4-hydroksynonenal (4-HNE) at 45 °C which yields a stable 
chromophore with maximal absorbance at 586 nm, then is subsequently analyzed using a micro  
plate reader. 
3.4. Assessment of Plasma Levels of ADMA, CGRP and Proinflammatory and  
Anti-Inflammatory Cytokines 
At the end of 3.5 h of I/R and immediately after GBF measurement was completed, the blood 
samples (about 3 mL) were taken from the vena cava for the measurement of plasma ADMA, CGRP, 
proinflammatory (TNF-α) and anti-inflammatory (IL-10) cytokines as described previously [13,60,61]. 
The CGRP level was measured by radioimmunoassay (RIA) in blood samples taken from the  
vena cava, using a specific CGRP antibody as described previously [60,61]. The rat CGRP-RIA kit 
was purchased from Phoenix Pharmaceuticals, Inc. (Belmont, CA, USA). The assay specificity showed 
100% cross-reactivity with rat CGRP and 35.5% cross-reactivity with human CGRP and no  
cross-reactivity with rat amylin, calcitonin and somatostatin-14. The limit of assay sensitivity was  
32 pg per tube; the intra-assay variation was less than 9% and the inter-assay variation was less than 4%. 
The concentration of ADMA in the blood was determined using ADMA direct rat ELISA kit 
manufactured by Immunodiagnostik AG (Enzo Life Sciences GMBH, Lorrach, Germany) according to 
the procedure recommended by the manufacturer and described previously [13]. Briefly, the aliquots 
(50 µL) of the pretreated standards, controls and samples were pipetted into wells of the microtitre 
plate and the antiserum solution (ADMA antibody, 50 µL) was added to each well. The plate was 
incubated for 15 h at 2–8 °C and washed four times with wash buffer. Subsequently, the enzyme 
conjugate solution (100 µL) was added to each well and then the microtitre plate was incubated for one 
hour at room temperature. The wells were again washed four times and the substrate solution (100 µL) 
Int. J. Mol. Sci. 2014, 15 4959 
 
 
was pipetted into the wells and the plate was incubated for 25 min. Then the reaction was stopped with 
stopping solution and the optical density was read at 450 nm using a microtitre plate reader. The limit 
of assay sensitivity was 3 pg per tube; the intra-assay variation was less than 7% and the inter-assay 
variation less than 4%. 
The plasma TNF-α and IL-10 concentrations levels were determined using a solid phase sandwich 
ELISA (BioSource International Inc., Camarillo, CA, USA) according to the manufacturer’s 
instructions. Briefly, each sample (50 µL) was incubated with biotinylated antibodies specific for rat  
TNF-α and IL-10 washed three times with assay buffer and finally conjugated with streptavidin 
peroxidase to form a complex with a stabilized chromogen as described before [13]. 
3.5. Statistical Analysis 
Results of the experiment were expressed as mean ± S.E.M and the statistical analysis was 
performed with ANOVA test and Tukey post hoc test where appropriate. Differences between 
estimates of effects were considered significant at p < 0.05. 
4. Conclusions  
We demonstrated that ADMA can exacerbate gastric injury when gastric mucosa is compromised 
by I/R. The deleterious effect of ADMA administration on I/R gastric lesions was ameliorated by the 
FXR agonist, GW4064. This beneficial protective effect of GW4064 could be explained in part, by an 
increase in DDAH1, which subsequently increased the metabolism of ADMA, and increased NO 
bioavailability. Moreover, we confirmed that the plasma circulating ADMA level and gastric MDA 
content are increased in animals exposed to I/R. We found that these effects are attenuated by  
L-arginine, SOD, and capsaicin, the latter applied in the small dose known to stimulate sensory afferent 
nerves and resulting in the release of vasodilatory mediators such as CGRP [18]. ADMA-induced 
aggravation of I/R gastric damaged mucosa was accompanied by a decrease in GBF and a rise in 
plasma ADMA levels, which correlated with reduced NO release into the gastric lumen and was 
accompanied by the impairment of CGRP release from sensory nerves. The ADMA aggravation of  
I/R damage in rats with intact sensory nerves and the accompanying decrease in plasma CGRP 
concentration in capsaicin-denervated rats was counteracted by supplementation of exogenous CGRP 
added to ADMA-treated rats with and without capsaicin denervation. We conclude that the impairment 
of gastric mucosal defense by treatment with ADMA, as manifested by exacerbation of I/R-induced 
gastric lesions, involves a decrease in gastric microcirculation mediated by the fall in NO and CGRP, 
and the enhanced lipid peroxidation and proinflammatory action of this NO synthase inhibitor. 
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